BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250325
DTEND;VALUE=DATE:20250328
DTSTAMP:20260515T112538
CREATED:20241127T122738Z
LAST-MODIFIED:20241127T122738Z
UID:40140-1742860800-1743119999@www.pharmajournalist.com
SUMMARY:4th Novel Conjugate Summit
DESCRIPTION:The field of conjugatable drugs is advancing at a rapid pace\, with major collaborations like Nurix & Pfizer for antibody-degrader conjugates and Bicycle & Novartis for radiopharmaceuticals\, which paves the way towards a new generation of more targeted\, safer and efficacious novel conjugated drugs. \nThe 4th Novel Conjugates Summit is the only event offering comprehensive insights into the latest innovations in bioconjugates. From antibody-degrader conjugates to bispecific ADCs and peptide drug conjugates\, join us to delve into each of their value propositions and navigate crucial considerations like target selection\, PK/PD profiles\, and translation into the clinic. \nConnect with 100+ experts from big pharma\, cutting-edge biotechs and conjugation and manufacturing providers\, all sharing crucial insights on striking success with new formats and payloads. \nNow is the time to expand your conjugate design toolkit to pursue emerging cancer targets and stay ahead in the race to deliver safer\, more targeted therapies beyond traditional ADCs Join us to explore the most promising new targeting vectors and payloads that are set to revolutionize the landscape of conjugated drugs in 2025!
URL:http://www.pharmajournalist.com/event/4th-novel-conjugate-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250325
DTEND;VALUE=DATE:20250328
DTSTAMP:20260515T112538
CREATED:20241127T125100Z
LAST-MODIFIED:20241127T125100Z
UID:40163-1742860800-1743119999@www.pharmajournalist.com
SUMMARY:8th Gene Therapy Development Summit
DESCRIPTION:With 14 new gene therapy approvals in the last 18 months\, billion-dollar collaborations\, and the development of treatments for more common conditions\, the gene therapy field is rapidly gaining momentum and broadening scope beyond rare diseases. \nReturning to Boston in March\, the 8th Gene Therapy Development Summit\, formerly known as the Gene Therapy for Rare Disorders Summit\, will unite 200+ gene therapy experts to tackle the field’s biggest challenges of achieving genuine scalability and accessibility to meet growing patient demand. \nFor the first time\, this industry-defining meeting will reflect the field’s growing focus on developing therapies for common diseases\, whilst addressing existing hurdles in rare and ultra-rare disorders. This is your unparalleled opportunity to delve into: \n\nThe latest global regulatory requirements\nOptimizing routes for CNS\nOcular and inner ear disorders\nInnovations in capsid engineering and dosing strategies\nIncreasing volumetric productivity to reduce CoGs\n\nVIEW THE FULL EVENT GUIDE \nSecure your place here or get in touch with the team – info@hansonwade.com
URL:http://www.pharmajournalist.com/event/8th-gene-therapy-development-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:General Enquiries: info@hansonwade.com or Partnership Enquiries: sponsor@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250325
DTEND;VALUE=DATE:20250328
DTSTAMP:20260515T112538
CREATED:20241212T121823Z
LAST-MODIFIED:20241212T121823Z
UID:40241-1742860800-1743119999@www.pharmajournalist.com
SUMMARY:2nd Biophysics for Drug Discovery Summit
DESCRIPTION:In today’s complex drug development landscape\, leveraging biophysical tools to unravel the molecular and target engagement intricacies of drug candidates is more critical than ever for successfully advancing molecules through the drug development pipeline. The 2nd Biophysics for Drug Discovery Summit is your exclusive opportunity to unite and network with your biophysics and drug discovery peers and delve into the application of biophysical techniques including SPR\, NMR\, Thermal shift assays\, mass spec\, and the emerging technologies\, across modalities and targets to inform efficient drug discovery. \n \nThe Biophysics for Drug Discovery Summit will delve into the latest in strategy and application of biophysical techniques across novel targets and modalities\, from AI-driven drug discovery to fragment-based drug discovery\, and in-cell biophysics to single-particle tracking. By understanding the intricate molecular mechanisms and improving hit selection and target identification\, we can accelerate the discovery of innovative therapies and improve the effectiveness and efficiency of drug development. \nUnlock the future of therapeutics through biophysics and keep up to date as field evolves into new technologies and applications\, this meeting will provide you with thought-provoking insights on biophysics applications to take away to your wider drug discovery teams. Join the Biophysics for Drug Discovery Summit in March 2025 and build meaningful connections with 70+ biophysicists and drug discovery experts and move the field forward with unique insights and deep-dive conversations. \nTo know more visit: https://ter.li/8u0s3n
URL:http://www.pharmajournalist.com/event/2nd-biophysics-for-drug-discovery-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250325
DTEND;VALUE=DATE:20250328
DTSTAMP:20260515T112538
CREATED:20250116T124349Z
LAST-MODIFIED:20250116T124349Z
UID:40335-1742860800-1743119999@www.pharmajournalist.com
SUMMARY:2nd EHS for Biopharma Summit East
DESCRIPTION:As the biopharma industry evolves with rapid advancements in drug development\, manufacturing\, and research\, EHS leaders are tasked with safeguarding employee health\, maintaining a culture of safety\, and addressing environmental concerns. Navigating these challenges while meeting sustainability goals and mitigating risks has become essential for operational success. EHS professionals must continuously adapt to this dynamic landscape to protect their most valuable asset: their workforce. \nThe 2nd EHS for Biopharma East Summit is an essential event for EHS professionals working in the biopharma industry\, focused on overcoming the sector’s unique regulatory and operational challenges. With over 100+ attendees\, this summit will provide valuable insights on navigating evolving regulations\, optimizing safety protocols\, and enhancing environmental stewardship. Whether your goal is to strengthen safety culture\, reduce incidents\, or achieve sustainability targets\, the summit offers the tools\, knowledge\, and networking opportunities necessary to elevate EHS practices. \nWhat can you expect? – Your Definitive Guide to EHS for Biopharma \n\nDiscover actionable strategies for managing global EHS challenges with insights from Astellas\, MilliporeSigma\, and Elanco\nEnhance safety culture in laboratory and manufacturing settings with guidance from AstraZeneca\, Texcell\, and Cytovance\nLearn best practices for embedding EHS programs within the workforce\, fostering leadership buy-in\, employee engagement\, and promoting psychological well-being to minimize burnout\nExplore the latest technologies driving EHS excellence with expertise from AstraZeneca and Sanofi\nConnect with industry peers to network and benchmark best practices.\nEarn continuing education credits from BCSP\, ABSA\, and CIH\n\nCreated for EHS professionals spanning EHS directors\, EHS managers and EHS technical experts focused on workplace safety\, environmental compliance\, and operational excellence. \nJoin us this March \nFind out more here \nRegister your place
URL:http://www.pharmajournalist.com/event/2nd-ehs-for-biopharma-summit-east/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250325
DTEND;VALUE=DATE:20250328
DTSTAMP:20260515T112538
CREATED:20250123T121746Z
LAST-MODIFIED:20250123T121746Z
UID:40347-1742860800-1743119999@www.pharmajournalist.com
SUMMARY:7th Treg-Directed Therapies Summit
DESCRIPTION:Over the past year\, the Treg sector has seen groundbreaking investments and strategic collaborations between leading biotech and pharma companies like Quell and AstraZeneca\, and Parvus and AbbVie\, creating a surge of innovation and spotlighting Treg cell therapies and modulators as the next frontier in autoimmune and inflammatory disease treatments. Tregs hold the potential to revolutionize care for conditions that have long lacked effective solutions and are the future of precision medicine in autoimmune and inflammatory diseases. \n \nThe 7th Treg-Directed Therapies Summit is your premier event dedicated to exploring and overcoming the unique challenges and advancements specific to Treg. Offering you exclusive access to the latest industry insights\, clinical data\, Treg biology breakthroughs and strategies for advancing therapies to the clinic from trailblazing companies and academic leaders\, including Abata Therapeutics\, Harvard Medical School\, Nektar Therapeutics\, Parvus Therapeutics\, PolTreg\, ThyTech and many more! \nWhether you are in discovery\, navigating the complexities of IND filings\, or transitioning to the clinic\, this forum provides an unparalleled opportunity to engage with leaders at the forefront of cell therapy and modulator innovation. Connect with senior experts in cell therapy manufacturing and modulator production\, build strategic relationships with investors\, pharmaceutical companies and academics\, opening doors to future collaborations and partnership opportunities. \nEvent guide link: https://ter.li/adqtg1
URL:http://www.pharmajournalist.com/event/7th-treg-directed-therapies-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR